Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Boston Announces Canadian Approval, Launch Of PROMUS Element Plus Stent System

RELATED NEWS
Trade BSX now with 

Boston Scientific Corp. (BSX: Quote) announced Health Canada approval and market launch of the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in Canada.

According to the company, the new stent system incorporates the platinum chromium alloy and innovative stent design of the PROMUS Element Stent with an enhanced catheter delivery system engineered for improved performance in treating patients with coronary artery disease. The company noted that it plans to begin marketing the product immediately in Canada.

Click here to receive FREE breaking news email alerts for Boston Scientific Corp and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Economic confidence in the eurozone picked up in October from a 10-month low, with broad based improvement across sectors, the results of a survey by the European Commission showed Thursday. The economic confidence index rose unexpectedly to 100.7 in October from 99.9 in the prior month. The score was expected to fall to 99.7. Visa Inc., the world's largest payment card processor, said Wednesday that its fourth quarter profit fell 10% from last year, hurt mainly by a hefty litigation provision even as revenue increased 9%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Stocks saw considerable volatility following the Federal Reserve's monetary policy meeting on Wednesday but maintained a negative bias before closing modestly lower. The losses on the day partly offset the rally seen in the previous session.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.